Trial Profile
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Cyclophosphamide; Epirubicin; Exemestane; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Paclitaxel; Tamoxifen
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms TP-II
- 06 Jun 2023 Results of translational pre-planned analysis assessing associations of gene expression signatures and sTILs with pCR presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Primary endpoint has been met. (Pathological complete response (pCR))
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology